A patient with Stage 4 chronic kidney disease (CKD) presents with hyperkalemia, anemia, and poorly controlled hypertension. Which nursing intervention is the most appropriate to address the patient's hyperkalemia?

A) Administer sodium polystyrene sulfonate as prescribed

B) Encourage intake of high-potassium foods

C) Increase the patient's fluid intake to flush out potassium

D) Hold all antihypertensive medications to prevent further kidney damage

A patient with Stage 4 Chronic Kidney Disease (CKD) presents with a potassium level of 5.8 mEq/L, serum creatinine of 2.3 mg/dL, and hemoglobin of 9.8 g/dL. Which of the following nursing interventions should be prioritized to address the immediate risk to the patient's health?

B) Initiate a low-potassium diet and consider pharmacological treatment for hyperkalemia

A) Administer erythropoiesis-stimulating agents for anemia

B) Initiate a low-potassium diet and consider pharmacological treatment for hyperkalemia

C) Encourage increased fluid intake to improve kidney filtration

D) Discuss options for renal replacement therapy with the healthcare provider

A patient with chronic kidney disease is being treated for hyperkalemia and anemia. Despite the reduction in serum potassium levels, the patient's blood pressure remains elevated. Which intervention should the nurse prioritize to address the patient's elevated blood pressure while providing renal protection?

A) Increase the dosage of the current antihypertensive medication.

C) Advise the patient to discontinue all potassium-rich foods.

D) Suggest the addition of a thiazide diuretic to the regimen.

A patient with chronic kidney disease (CKD) and hyperkalemia has been started on sodium polystyrene sulfonate and dietary potassium restrictions. Her serum potassium level is now 5.1 mEq/L. The healthcare team plans to add a mineralocorticoid receptor antagonist to her regimen. Which of the following nursing interventions is most important to prioritize at this time?

B) Monitor the patient for signs of fluid overload and hypertension.

A) Educate the patient on the signs and symptoms of hypokalemia.

B) Monitor the patient for signs of fluid overload and hypertension.

C) Instruct the patient to avoid foods high in sodium.

D) Assess the patient for signs of anemia and fatigue.

A patient with chronic kidney disease presents with hypocalcemia, hyperphosphatemia, and new symptoms of fatigue and muscle weakness. The healthcare team has introduced phosphate binders and low-dose calcium supplements to manage these issues. Which nursing intervention is most appropriate to help prevent complications related to these electrolyte imbalances?

B) Educate the patient on the importance of taking phosphate binders with meals.

A) Encourage the patient to consume dairy products to increase calcium levels.

B) Educate the patient on the importance of taking phosphate binders with meals.

C) Advise the patient to limit fluid intake to reduce potassium levels.

D) Suggest the patient increase dietary protein to improve muscle strength.

A patient with chronic kidney disease is experiencing hypocalcemia and hyperphosphatemia. The healthcare team has introduced phosphate binders and calcium supplements as part of the management plan. Which nursing intervention is most important to prioritize in this situation?

A) Educate the patient on the importance of taking phosphate binders with meals.

B) Monitor the patient's blood pressure daily.

C) Advise the patient to increase intake of potassium-rich foods.

D) Encourage the patient to skip doses of calcium supplements if they experience constipation.

A patient with chronic kidney disease is experiencing fatigue, muscle weakness, and palpitations, with lab results showing low serum calcium, elevated phosphorus, and anemia. Which nursing intervention should be prioritized to address these symptoms and stabilize her condition?

D) Initiate erythropoiesis-stimulating agents to manage anemia.

A) Increase dietary protein intake to improve albumin levels.

B) Administer calcium supplements to address electrolyte imbalance.

C) Educate the patient on reducing dietary phosphorus intake.

D) Initiate erythropoiesis-stimulating agents to manage anemia.

A patient with chronic kidney disease presents with fatigue, pallor, muscle weakness, and palpitations. Lab results reveal hypocalcemia, hyperphosphatemia, hypoalbuminemia, and anemia. Which of the following interventions should the nurse prioritize to address the patient’s fatigue and weakness?

C) Initiate erythropoiesis-stimulating agents to treat anemia.

A) Administer calcium supplements to correct hypocalcemia.

B) Increase the dosage of phosphate binders to manage hyperphosphatemia.

C) Initiate erythropoiesis-stimulating agents to treat anemia.

D) Encourage a high-protein diet to improve hypoalbuminemia.

A patient with chronic kidney disease (CKD) presents with ongoing anemia, elevated phosphorus levels, and newly increased frequency of premature ventricular contractions. Given these findings, what is the most appropriate nursing intervention to prioritize during this visit?

C) Reinforce adherence to prescribed phosphate binders and dietary phosphorus restrictions.

A) Educate the patient on increasing dietary protein intake to address hypoalbuminemia.

B) Encourage the patient to maintain a low-sodium diet to manage blood pressure.

C) Reinforce adherence to prescribed phosphate binders and dietary phosphorus restrictions.

D) Advise the patient to increase fluid intake to promote kidney function.

A patient with chronic kidney disease presents with persistent fatigue, dizziness, and lightheadedness. Her serum calcium level has improved, but serum phosphorus remains elevated despite increased phosphate binder dosage. Her albumin is low, and she has frequent premature ventricular contractions. What should be the nurse's priority intervention to address her symptoms and lab findings?

C) Monitor cardiac rhythm closely and expedite cardiology consultation due to increased arrhythmias.

A) Increase the dosage of erythropoiesis-stimulating agents to further improve hemoglobin levels.

B) Collaborate with the dietitian to enhance protein intake and consider albumin supplementation.

C) Monitor cardiac rhythm closely and expedite cardiology consultation due to increased arrhythmias.

D) Encourage the patient to increase physical activity to improve muscle weakness and fatigue.

Chronic kidney disease - Nursing Case Study

Pathophysiology

• Primary mechanism: Nephron Damage and Loss - Chronic kidney disease (CKD) primarily results from progressive nephron damage due to conditions like diabetes and hypertension. This damage leads to glomerular sclerosis and tubular atrophy, reducing kidney filtration capacity.

• Secondary mechanism: Compensatory Hyperfiltration - As functioning nephrons are lost, remaining nephrons undergo hyperfiltration to maintain GFR. This adaptive response increases intraglomerular pressure, accelerating further nephron injury and scarring.

• Key complication: Uremic Toxin Accumulation - Reduced kidney function impairs waste excretion, leading to toxin buildup in the blood. This contributes to systemic complications such as cardiovascular issues and metabolic imbalances, highlighting the importance of early intervention in CKD management.

Patient Profile

Demographics:

57-year-old female, retired school teacher

History:

• Key past medical history: Hypertension for 15 years, Type 2 Diabetes Mellitus for 10 years

• Current medications: Lisinopril 20 mg daily, Metformin 500 mg twice daily, Amlodipine 5 mg daily, Atorvastatin 20 mg daily

• Allergies: Penicillin

Current Presentation:

• Chief complaint: Increasing fatigue and swelling in the legs

• Key symptoms: Persistent fatigue, lower extremity edema, nocturia, decreased appetite

• Vital signs: Blood pressure 162/98 mmHg, heart rate 88 bpm, respiratory rate 20 breaths per minute, temperature 98.4°F, oxygen saturation 95% on room air

Section 1

New Diagnostic Results:

Following the initial presentation, the patient underwent a series of diagnostic tests to further evaluate the extent of her chronic kidney disease and its complications. The lab results revealed a serum creatinine level of 2.3 mg/dL, indicating a significant reduction in glomerular filtration rate (GFR), estimated at approximately 28 mL/min/1.73 m², classifying her CKD as Stage 4. Her blood urea nitrogen (BUN) was elevated at 45 mg/dL, further supporting the presence of reduced kidney function and the accumulation of uremic toxins. Electrolyte imbalances were also noted, with a potassium level of 5.8 mEq/L, highlighting the risk of hyperkalemia, which could potentially lead to cardiac complications. Additionally, the patient's hemoglobin level was found to be 9.8 g/dL, indicating anemia, a common complication of CKD due to decreased erythropoietin production by the damaged kidneys.

Urinalysis showed significant proteinuria with a protein-to-creatinine ratio of 2.5 g/g, suggesting ongoing nephron damage and increased permeability of the glomerular filtration barrier. The presence of microalbuminuria indicates that the patient's CKD is strongly influenced by her longstanding diabetes and hypertension, necessitating tighter control of these conditions to slow progression. The patient's lipid profile remained stable, with LDL cholesterol at 98 mg/dL, thanks to atorvastatin therapy, yet her blood pressure remains inadequately controlled, as evidenced by her elevated readings.

These diagnostic findings underscore the need for a comprehensive treatment plan that addresses not only the renal aspects of her condition but also the associated cardiovascular risks. The healthcare team considers intensifying her antihypertensive regimen and initiating treatment for hyperkalemia and anemia. These steps aim to stabilize her condition and prevent further deterioration of kidney function, while ongoing monitoring and patient education will be crucial in managing her CKD and enhancing her quality of life.

Section 2

The healthcare team decides to focus initially on managing the patient's hyperkalemia and anemia, as these conditions pose immediate risks. Potassium-binding agents, such as sodium polystyrene sulfonate, are initiated to lower the serum potassium levels. Alongside this, the patient receives dietary counseling to reduce potassium intake, focusing on avoiding high-potassium foods like bananas, oranges, and potatoes. Repeat serum potassium levels are planned for the next 24 hours to monitor the effectiveness of these interventions. Additionally, erythropoiesis-stimulating agents (ESAs) are prescribed to address the anemia, aiming to increase her hemoglobin levels gradually and improve her energy levels and overall well-being.

Upon follow-up, the patient's serum potassium level decreases to 5.1 mEq/L, indicating a positive response to treatment. However, her blood pressure remains elevated at 158/92 mmHg despite her current antihypertensive regimen. The healthcare team considers adding a mineralocorticoid receptor antagonist to her treatment plan to provide more effective blood pressure control and offer additional renal protection. Alongside pharmacological interventions, the patient is educated on low-sodium dietary modifications and the importance of medication adherence.

As the patient's journey continues, the healthcare team remains vigilant for potential new complications. Her lab results continue to be monitored regularly to assess kidney function, electrolyte balance, and hemoglobin levels. The integration of lifestyle changes, medication adjustments, and close monitoring aims to stabilize her condition, reduce cardiovascular risks, and slow the progression of her CKD. The team emphasizes the importance of tight glycemic control and regular follow-ups with her primary care provider and nephrologist to optimize care and enhance her quality of life.

Section 3

Several weeks into the management plan, the patient begins to exhibit new symptoms, prompting further evaluation by the healthcare team. During a routine follow-up appointment, the patient reports experiencing increased fatigue, muscle weakness, and occasional palpitations. Her latest lab results reveal a serum calcium level of 7.8 mg/dL, indicating hypocalcemia, and a serum phosphorus level of 5.6 mg/dL, suggesting hyperphosphatemia. These imbalances are potential complications of her chronic kidney disease, likely exacerbated by the decreased renal function and dietary restrictions she is following.

In response to these new complications, the healthcare team considers the introduction of phosphate binders to reduce serum phosphorus levels and prevent further decline in calcium levels. Concurrently, the patient is advised to increase her intake of calcium-rich foods, balancing this with her potassium restrictions, and is started on a low-dose calcium supplement. The team also evaluates her current vitamin D status, as vitamin D deficiency could be contributing to her hypocalcemia, and considers supplementation to enhance calcium absorption.

These developments necessitate close monitoring of her calcium-phosphorus product and vigilance for signs of vascular calcification. The healthcare team emphasizes the importance of adhering to the updated dietary and medication regimen and schedules more frequent follow-ups to reassess her electrolyte balance and overall condition. This strategic approach aims to manage these complications effectively while preventing further progression of her chronic kidney disease, thereby enhancing her quality of life and reducing the risk of cardiovascular events.

Section 4

Two weeks after the implementation of the revised management plan, the patient returns for a follow-up appointment. During the initial assessment, the nurse notes that the patient appears more fatigued than before, with pallor evident upon inspection. She reports persistent muscle weakness, which has begun to interfere with her daily activities, and mentions experiencing more frequent episodes of palpitations. Vital signs reveal a blood pressure of 140/90 mmHg, heart rate of 98 beats per minute, and respiratory rate of 20 breaths per minute, with no fever. The nurse also observes mild bilateral lower extremity edema.

The latest lab results indicate a serum calcium level of 8.2 mg/dL, showing a slight improvement but still below the normal range. Serum phosphorus remains elevated at 5.4 mg/dL, despite the introduction of phosphate binders. Additionally, her serum albumin level is 3.2 g/dL, suggesting mild hypoalbuminemia, which could be contributing to her symptoms of fatigue and weakness. An electrocardiogram reveals occasional premature ventricular contractions, correlating with her reports of palpitations. Her hemoglobin level has dropped to 10.5 g/dL, indicating anemia, likely anemia of chronic disease, compounded by her kidney dysfunction.

In response to these findings, the healthcare team considers adjusting her phosphate binder dosage and reevaluates her dietary phosphate intake. They discuss the possibility of introducing erythropoiesis-stimulating agents to address her anemia and improve her energy levels. The team also emphasizes the importance of monitoring her cardiovascular status, given the arrhythmias, and schedules a cardiology consultation to better assess her risk of cardiac complications. This comprehensive approach aims to stabilize her condition, prevent further progression of her chronic kidney disease, and enhance her quality of life by addressing the interconnected issues of electrolyte imbalance, anemia, and potential cardiovascular risks.

Section 5

Two weeks later, the patient returns for another follow-up appointment. The nurse notes that while her pallor has slightly improved, the patient still appears fatigued, and she now reports new symptoms of dizziness and occasional lightheadedness. Her muscle weakness persists, and she has been experiencing increased difficulty concentrating, which has impacted her ability to perform her job effectively. Upon examination, her vital signs show a blood pressure of 130/85 mmHg, a heart rate of 105 beats per minute, and a respiratory rate of 18 breaths per minute. The mild bilateral lower extremity edema has not worsened, but the patient mentions a sensation of tightness in her legs.

New laboratory results reveal that her serum calcium level has further improved to 8.5 mg/dL, but her serum phosphorus remains elevated at 5.1 mg/dL, despite dietary modifications and increased phosphate binder dosage. Her serum albumin has decreased slightly to 3.0 g/dL, suggesting ongoing issues with protein balance. Notably, her hemoglobin has increased to 11.2 g/dL after the introduction of erythropoiesis-stimulating agents, but her hematocrit level remains low at 33%, indicative of her continued anemia. An updated electrocardiogram shows more frequent premature ventricular contractions, raising concerns about her cardiovascular stability.

In response to these findings, the healthcare team decides to increase the intensity of her phosphate management and considers further adjustments to her diet and medication regimen. The cardiology consultation is expedited due to the increased frequency of arrhythmias and her reports of dizziness, which could signify underlying cardiac issues. The team also discusses the potential need for further interventions to address her hypoalbuminemia, which may involve nutritional support or supplementation. This proactive approach aims to mitigate the progression of her kidney disease, address the interconnected complications, and improve her overall functional status and quality of life.